These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 20078498)

  • 1. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
    J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenic effects of ribavirin in vivo.
    Perelson AS; Ribeiro RM
    J Hepatol; 2005 Oct; 43(4):553-5. PubMed ID: 16099528
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future treatment of chronic hepatitis C.
    Keeffe EB
    Antivir Ther; 2007; 12(7):1015-25. PubMed ID: 18018759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
    Olaso V; Córdoba J; Molina JM; López B; Siles MS; Monte E; Calvo F; Bau I; Beltrán B; Martínez B; Gobernado M
    Rev Esp Quimioter; 2002 Dec; 15(4):366-73. PubMed ID: 12587043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of recurrent hepatitis C after liver transplantation: a concise review.
    Szabo G; Katz E; Bonkovsky HL
    Am J Gastroenterol; 2000 Sep; 95(9):2164-70. PubMed ID: 11007212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?
    Aghemo A; Rumi MG; Prati GM; Colombo M
    Hepatology; 2009 Feb; 49(2):702-3; author reply 703-4. PubMed ID: 19177585
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response.
    Shiffman ML; Hofmann CM; Sterling RK; Luketic VA; Contos MJ; Sanyal AJ
    J Infect Dis; 2001 Aug; 184(4):405-9. PubMed ID: 11471097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and subacute oral toxicity study on the flavonoid rich fraction of Monodora tenuifolia seed in albino rats.
    Ekeanyanwu RC; Njoku OU
    Asian Pac J Trop Biomed; 2014 Mar; 4(3):194-202. PubMed ID: 25182437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards predicting the therapeutic response in patients with hepatitis C.
    Féray C
    Aliment Pharmacol Ther; 2010 Jan; 31(2):339-40; author reply 340-1. PubMed ID: 20078498
    [No Abstract]   [Full Text] [Related]  

  • 16. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C].
    Olaso V; Córdoba J; Lòpez Viedma B; Siles MS; Molina JM; Prieto M; Baum I; Gobernado M; Berenguer J
    Rev Esp Quimioter; 1999 Sep; 12(3):220-8. PubMed ID: 10878512
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.